What's new
Newsletters "UptoDate" of BASG/AGES MEA are published monthly and contain the latest articles from the last month (link to subscription page).
For the RSS feed with daily notification of updates, use the link: RSS feed to "what's new".
Searched for "active".
Replacement
|
Medicines
|
10/02/2011
The marketing authorization holder has informed its supplied customers that results from stability data indicate a possible shortfall of the required active ingredient content by the end of the shelf life. The affected batch currently meets all…
22/11/2010
Assessment of the Advisory Board on Classification regarding Lipid Control Pflanzlicher Fettbinder (German only)
Referenced at:
messages in brief
|
11/11/2010
Due to a given occasion and due to inquiries regarding "innovations" in the field of traditional herbal medicinal products, the Federal Office for Safety in Health Care takes the liberty to inform about the current legal situation. The background of…
messages in brief
|
13/08/2010
The Federal Office for Safety in Health Care (BASG) publishes the following statement on "Calcium Supplementation and Myocardial Infarction Risk." It refers to a meta-analysis on the use of calcium as monotherapy for osteoporosis published in the…
messages in brief
|
29/03/2010
On March 29, 2010, the delivery of generic drugs containing Clopidogrel, which used the active ingredient of the supplier Glochem Industries Ltd., was stopped for the time being on wholesale level by BASG/AGES PharmMed. It was determined that the…
02/12/2009
Assessment of the Advisory Board on Classification regarding active+med Magen-Darm-Pastillen (German only)
Referenced at:
messages in brief
|
05/10/2009
PSUR Worksharing - Europe adopts Austrian practice
07/08/2009
Assessment of the Advisory Board on Classification regarding active+med Wund- und Sonnenbrandsalbe (German only)
Referenced at:
messages in brief
|
31/03/2009
In January 2009, AGES PharmMed conducted the second customer survey since its foundation in 2006. As in the previous survey, marketing authorization holders of proprietary medicinal products were addressed. In contrast to the first survey, the survey…